Abstract

Sandoz says it will invest $50 million to expand production capacity for finished-dosage penicillin at its plant in Kundl, Austria. The company, a leading supplier of generic and biosimilar medicines, last year announced a $100 million investment in the site to manufacture the active pharmaceutical ingredient (API) in oral amoxicillin. The investments are part of Sandoz’s $250 million expansion in antibiotics manufacturing at its European sites, including a $50 million project unveiled in 2021 to bolster sterile API production in Palafolls, Spain.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.